Verrica Pharmaceuticals
Update in progressVRCA (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Verrica Pharmaceuticals is a dermatology-focused company developing and commercializing treatments for skin diseases in the United States. Its lead product, YCANTH (VP-102), is a GMP-formulated cantharidin drug-device combo for molluscum contagiosum in adults and children and for common warts. VP-315 is an injectable oncolytic peptide in Phase II for dermatologic cancers, including basal cell carcinoma. Partners include Torii (Japan) and Lytix Biopharma for VP-315. Founded 2013, based in West Chester, PA.
Company score
- Sentiment
- -0.21
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.12
- Governance
- -0.43
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.13
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Jayson M. Rieger M.B.A., Ph.D.
- Founded2013
- Employees76
- Websitewww.verrica.com
Identifiers
- ISINUS92511W1080
- FIGIBBG00L03BYB7
- LEI5493002L68H6THU5GW50
- CUSIP92511W108
- CIK0001660334